Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC
This review organizes biomarkers by the treatment decision they are expected to support, which covers curative intent and locoregional risk stratification, molecularly guided systemic therapy, immune-state assessment, dynamic monitoring, resistance reassessment, and translational readiness.